Akero Therapeutics, Inc.
Akero acquires by Novo Nordisk, significant cash payout.
1 source·09/12, 14:14·sec.gov
Merger with Novo Nordisk approved by shareholders.
1 source·03/12, 15:44·sec.gov
10-Q form submitted!
1 source·07/11, 22:12·sec.gov
Akero announces merger with Novo Nordisk for $60 per share.
1 source·09/10, 20:34·sec.gov
Akero pays off $37.6 million loan to Hercules.
1 source·29/09, 20:06·sec.gov
Routine 8-K filing with no major news.
1 source·08/08, 11:38·sec.gov
10-Q form submitted!
1 source·08/08, 11:32·sec.gov
Annual meeting held; directors and auditors approved.
1 source·04/06, 20:06·sec.gov
Akero explores sale as stock jumps 24.72%.
1 source·21/05, 03:57·finviz.com
Akero shows promise with MASH treatment and analyst support.
1 source·13/05, 12:12·finviz.com
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
·finviz.com·09/05, 11:51
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
·finviz.com·09/05, 11:18
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
·finviz.com·09/05, 10:18